Delivery Order SPE2DB20D2014-SPE2DB25FC95J
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $8,962.67 under a firm fixed price structure, with an ultimate completion date of August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $17,662.48 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count package) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitive, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 and extends through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $6,100.80 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $5,618.36 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The delivery...
- The Defense Logistics Agency awarded a $5,629.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, which is also the headquarters location of the prime contractor. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $8,001.71. This is a firm fixed price, non-competitive delivery order executed under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The order will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $47,238.51 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitively awarded, firm fixed-price contract was executed on September 9, 2025, with completion targeted for September 10, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,119.21 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This is a firm fixed-price, competitively awarded delivery order with an ultimate completion date of July 22, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $4,328.04 under firm fixed-price terms, with an ultimate completion date of July 31, 2025. The pharmaceutical products will be delivered to the contracting location in Conshohocken, Pennsylvania, where...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC95JDelivery Order
The Defense Logistics Agency awarded a $18,875.65 delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count) with an ultimate completion date of September 10, 2025. This is a firm fixed-price, non-set-aside contract with performance occurring at the vendor's Conshohocken, Pennsylvania location. The delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling value and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor that supplies a comprehensive range of medications and medical commodities to military and veteran healthcare systems. The company's DLA Troop Support Medical IDC serves as a global pharmaceutical support vehicle enabling delivery of specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains to support Defense Health Agency and other federal healthcare customers. This ondansetron order represents a routine pharmaceutical delivery under that comprehensive vehicle, reflecting the company's established capability to meet federal medical procurement requirements through competitive contracting.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.9k | 9/9/25 |